20.3 C
New York
Sunday, June 7, 2026

Tag: exercise

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering

New York, NY, June 05, 2026 (GLOBE NEWSWIRE) -- InterPrivate Investment Partners V, Inc. (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced the closing of its initial public offering of 20,125,000 units, including 2,625,000 units issued pursuant to the exercise of the underwriters’ over-allotment option in full, at a price of $10.00 per unit on June 5, 2026. Total gross proceeds from the offering were $201.25 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Re: TriWest IV’s Holdings in Source Energy Services Ltd.

CALGARY, AB, June 5, 2026 /CNW/ - TriWest Capital Partners IV (US), L.P., SES Sand Holdings (Canada) LP, SES Sand Holdings 2 (Canada) LP...

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

Power Metallic Mines Files Amended LIFE Offering Document to include Quebec as an Offering Jurisdiction for previously announced Brokered LIFE Offering for Gross Proceeds...

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, June 5, 2026 /CNW/ - Power...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.

SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver

Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc. (SynbioTech),...

Long Table Growth Corp. Announces Closing of $172.5 Million Initial Public Offering Including Exercise of Underwriters’ Over-Allotment Option in Full

DALLAS, TX, June 05, 2026 (GLOBE NEWSWIRE) -- Long Table Growth Corp. (Nasdaq: LTGRU) (the “Company”) today announced the closing of its initial public offering of 17,250,000 units, which includes 2,250,000 units issued pursuant to the exercise by the underwriter of its over-allotment option in full, at a public offering price of $10.00 per unit. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share.

UREVO Debuts Smart Wellness Pop-Up in SoHo

UREVO Debuts Smart Wellness Pop-Up in SoHo--Three-day public experience during New York Tech Week showcases the future of active work and recovery

Zifo Transforms EHS Policy Management with New AI-Enabled Services Accelerator

AI-powered EHS Compliance services accelerator is purpose-designed for pharma, biotech, and medical device companiesCAMBRIDGE, Mass. and CAMBRIDGE, England, June 5, 2026 /PRNewswire/ -- Zifo,...

Zifo Transforms EHS Policy Management with New AI-Enabled Services Accelerator

AI-powered EHS Compliance services accelerator is purpose-designed for pharma, biotech, and medical device companiesCAMBRIDGE, Mass. and CAMBRIDGE, England, June 5, 2026 /PRNewswire/ -- Zifo,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsExercise